The lawsuit, filed by former Genzyme shareholders in 2015, alleged Sanofi intentionally slowed development of Lemtrada, Genzyme’s MS drug, to avoid paying the shareholders for regulatory and sales milestones.
The shareholders said they were due between $708 million and $3.8 billion depending on how quickly Lemtrada received FDA approval, according to BioPharma Dive.
The settlement does not include an admission of liability or wrongdoing from Sanofi.
Read the full article here.
More articles on pharmacy:
Amgen exits neuroscience research, cuts 180 US jobs
Walgreens’ exit from health clinic business should serve as a warning to rivals
Top 10 pharmacy stories in October
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
